Publications

5677 Results

Sex Differences in Risk of Severe Adverse Events in Patients Receiving Immunotherapy, Targeted Therapy, or Chemotherapy in Cancer Clinical Trials

Authors
J Unger;D Hershman
Journal / Conference
AACR Annual Meeting (April 14-19, 2023, Orlando, FL), major symposium presentation, SESSION SY43 - Sex Hormones and Cancer
Year
2023
Research Committee(s)
Cancer Care Delivery

Pathological response and exploratory analyses of neoadjuvant-adjuvant versus adjuvant pembrolizumab for resectable stage IIIB-IV melanoma from SWOG S1801

Authors
S Patel;M Othus;GP Wright;J Hyngstrom;C Lao;T Truong;S Chandra;K Kendra;C Devoe;A Hedge;A Mangla;M Lowe;E Buchbinder;J Kirkwood;E Sharon;L Korde;J Moon;V Sondak;A Ribas;V Prieto
Journal / Conference
ESMO (October 20-24, 2023, Madrid, Spain), LBA, accepted profferred paper presentation
Year
2023
Research Committee(s)
Melanoma
Study Number(s)
S1801

Surgical Quality for Patients treated with Neoadjuvant Chemotherapy versus Chemoradiation for locally advanced rectal cancer (LARC): Results from PROSPECT (Alliance N1048)

Authors
M Weiser;Q Shi;G Chang;J Goldberg;R Auer;M Gollub;L Saltz;B Musher;T Al Baghdadi;J Farma;T George;B Colgrove;G Nelson;E O'Reilly;A Shargill;J Meyerhardt;H Mamon;D Schrag
Journal / Conference
ESMO (October 20-24, 2023, Madrid, Spain), poster
Year
2023
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/N1048

Higher vincristine doses correlate with longer overall survival: a post-hoc analysis of participants receiving PCV on RTOG 9402

Authors
M Donovan;K Fink;M Mehta
Journal / Conference
Society for Neuro-Oncology Annual Meeting (SNO) (August 10-12, 2023, San Francisco, CA), poster
Year
2023
Research Committee(s)
Brain
Study Number(s)
SWOG-9402

Examining patient uptake of electronic patient-reported outcomes (ePRO) in a prospective clinical study of immune-related adverse events (IR-AEs)

Authors
R Vaidya;A Darke;K Gunturu;D Hershman;M Fisch;NL Henry;J Unger
Journal / Conference
JCO Oncol Pract 19, 2023 (suppl 11; abstr 368); ASCO Quality Care Symposium (October 27-28, 2023, Boston, MA), poster
Year
2023
Research Committee(s)
Symptom Management and Survivorship
Study Number(s)
S2013

Whole Genome Sequencing Informed Patient Personalized Measurable Residual Disease Assays for Acute Myeloid Leukemia (SWOG S0106)

Authors
N Ravindra;L Dillon;J Lack;C Dalgard;E vanCollenburg;A Corner;L Beppu;H Erba;M Othus;J Radich;C Hourigan
Journal / Conference
Journal of Molecular Diagnotics Volume 25;Issue 11, SupplementS1-S186; Association for Molecular Pathology (AMP) 2023 Conference (Nov 14-18, 2023, Salt Lake City, UT), poster
Year
2023
Research Committee(s)
Leukemia
Study Number(s)
S0106

Alliance A021602: Phase III, Double Blinded Study of Cabozantinib Versus Placebo for Advanced Neuroendocrine Tumors (NET) After Progression on Prior Therapy (CABINET)

Authors
J Chan;S Geyer;F Ou;M Knopp;S Behr;T Zemla;A Jacoba;A Shergill;E Wolin;T Halfdanarson;N Trikalinos;B Konda;N Vijayvergia;N Dasari;N Dasari;J Strosberg;E Kohn;M Kulke;E O'Reilly;J Meyerhardt
Journal / Conference
Annals of Oncology VOLUME 34, SUPPLEMENT 2, S1292; ESMO (October 20-24, 2023, Madrid, Spain), proferred paper presentation
Year
2023
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/A021602

PAPMET2 A Phase II Randomized Trial of Cabozantinib with or without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma (PRCC): SWOG S2200)

Authors
B Maughan;M Plets;S Pal;Y Ged;C Tangen;U Vaishampayan;SP Lerner;IM Thompson
Journal / Conference
IKCS North America (Nov 9-11, 2023, Nashville, TN), TIP poster
Year
2023
Research Committee(s)
Genitourinary
Study Number(s)
S2200

Impact of Dexamethasone (Dex) Dose Strength on Outcomes in Newly Diagnosed Multiple Myeloma (NDMM): A Secondary Analysis of SWOG Studies S0777 and S1211

Authors
R Banerjee;R Sexton;A Cowan;S Ailawadhi;V Rajkumar;S Kunnathu Kumar;S Lonial;B Barlogie;BGM Durie;S Usmani;A Hoering;R Orlowski
Journal / Conference
ASH Annual Meeting (Dec9-12,2023, San Diego, CA), oral
Year
2023
Research Committee(s)
Myeloma
Study Number(s)
S0777, S1211

Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study (SWOG S1925; NCT#04269902)

Authors
D Stephens;A Moseley;B Hill;M Shadman;M Fisch;A Danilov;D Ng;L Roeker;D Brander;V Banerji;M Othus;S O'Brien;H Erba
Journal / Conference
IWCLL (October 6-9, 2023, Boston, MA), TIP poster
Year
2023
Research Committee(s)
Leukemia
Study Number(s)
S1925